Can Numbness Be Undone?
OraVerse® can help you. By now, persisting desensitization is something many of us experience at the dentist after an injection of local anesthesia. Wouldn’t it be nice to get on with your day with your mouth feeling normal again? Dr. Louis R. Garcia now uses a sure-fire way that can speed up the return of feeling in the soft tissues of your mouth after routine care.
It’s time for OraVerse®!
Feeling numb can be restricting, affecting your ability to eat, drink, speak, and smile normally. You might even catch yourself drooling.
OraVerse® makes use of technology that effectively reverses unwanted persisting desensitization after routine care in which local anesthetic that contained a vasoconstrictor was used. In clinical trials, patients were able to regain normal feeling in approximately half the time. A similar ingredient used in OraVerse® has been used in other medical applications for many years. Today, the safety and effectiveness of OraVerse® has been sufficiently demonstrated in terms of dentistry.
Reversing You To Feeling Normal Again
Now, when you step out of our dental office, OraVerse® accompanies you – moving you comfortably and confidently back into your normal routine. And if you feel more like yourself, aren’t you more productive?
The typical duration of soft tissue numbness following the use of a local dental anesthetic is 3-5 hours. This desensitization results in problems with speaking, smiling, eating and drinking normally, and even in drooling. OraVerse® is administered by your doctor immediately following the procedure, allowing for a return to normal sensation and function in about half the time. That’s time you can put back in your day… doing what you want without limitations caused by persisting desensitization.
Important Safety Information: Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are not common with OraVerse® (phentolamine mesylate), clinicians should still be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease. Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse®, myocardial infarction, cerebrovascular spasm and occlusion have been reported, typically in association with marked hypotensive episodes producing shock-like states. OraVerse® is not recommended for use in children less than 6 years of age or weighing less than 33 lbs.